In a phase I/II study, osimertinib (80 mg/day) exhibited limited clinical activity in patients harboring EGFR ex20ins mutation (mPFS: 3.8 months; mOS: 15.8 months; ORR: 0%).[18] In 2 other prospective studies,[19,20] the use of osimertinib (160 mg/day) as first- and later-line treatment in NSCLC patients harboring the EGFR ex20ins mutation showed moderate efficacy (mPFS: 6.8–9.7 months; ORR: 24%–28%). This evidence concerns the gene EGFR and non-small cell lung carcinoma.